胞苷脱氨酶
体细胞突变
突变
生物
APOBEC3G公司
癌症
阿波贝克
基因组不稳定性
遗传学
癌症的体细胞进化
癌症研究
膀胱癌
插入突变
癌细胞
突变
基因组
基因
DNA损伤
DNA
抗体
B细胞
作者
Weisi Liu,Kevin P. Newhall,Francesca Khani,LaMont Barlow,Duy Nguyen,Lilly Gu,Kenneth Wha Eng,Bhavneet Bhinder,Manik Uppal,Charlotte Récapet,Andrea Sboner,Susan R. Ross,Olivier Elemento,Linda Chelico,Bishoy M. Faltas
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2022-12-08
卷期号:83 (4): 506-520
被引量:28
标识
DOI:10.1158/0008-5472.can-22-2912
摘要
Abstract Mutagenic processes leave distinct signatures in cancer genomes. The mutational signatures attributed to APOBEC3 cytidine deaminases are pervasive in human cancers. However, data linking individual APOBEC3 proteins to cancer mutagenesis in vivo are limited. Here, we showed that transgenic expression of human APOBEC3G promotes mutagenesis, genomic instability, and kataegis, leading to shorter survival in a murine bladder cancer model. Acting as mutagenic fuel, APOBEC3G increased the clonal diversity of bladder cancer, driving divergent cancer evolution. Characterization of the single-base substitution signature induced by APOBEC3G in vivo established the induction of a mutational signature distinct from those caused by APOBEC3A and APOBEC3B. Analysis of thousands of human cancers revealed the contribution of APOBEC3G to the mutational profiles of multiple cancer types, including bladder cancer. Overall, this study dissects the mutagenic impact of APOBEC3G on the bladder cancer genome, identifying that it contributes to genomic instability, tumor mutational burden, copy-number loss events, and clonal diversity. Significance: APOBEC3G plays a role in cancer mutagenesis and clonal heterogeneity, which can potentially inform future therapeutic efforts that restrict tumor evolution. See related commentary by Caswell and Swanton, p. 487
科研通智能强力驱动
Strongly Powered by AbleSci AI